Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and favorable inventory movements. Biktarvy generated $4.1 billion. Adjusted quarterly earnings reached $2.55 per share, compared with $2.47 a year earlier, while reported EPS fell to $1.94. Despite the sales upgrade, Gilead widened its forecast adjusted annual l
0